Upload
others
View
0
Download
0
Embed Size (px)
Citation preview
MédiS GROUP
MédiS GROUP and its
subsidiaries
MédiS GROUP
AN INTERNATIONAL PHARMACEUTICAL
GROUP
Manufactures and markets generic
medicines which comply withINTERNATIONAL STANDARDS
MédiS GROUP
Tunisia
Algeria
Senegal
Czech
Republic
KEY DATES
Creation of MédiS
The beginning of a story …
Creation of the
subsidiary
INPHA-MédiSin Algeria
The first MAA Creation of
MédiS
INTERNATIONAL
in Czech Republic
Launch of the
Biosimilars project
Entry in the
TOP 10
MédiS : leader of
local industries
Creation of
NEAPOLIS
PHARMAOncology and DPI
Creation of MédiS GROUP
manufacturing
license
of DPI Unit
Acquisition
of WPS
► MédiSSENEGAL
Creation of
TUNIVET
Manufacturing and marketing
of Medicines in ALGERIA
THE LARGEST INJECTABLES SITE IN THE MENA
2006Merging and creation :
INPHA-MédiS: Specialized
in liquid forms
2010Extension :
Manufacturing of
dry forms
2013/14Beginning of construction
NEW site of production :
DPI & Injectable forms
2016Ranking TOP 20
laboratories
2017/18Manufacturing license of the new
site and beginning of
production
Manufacturing and marketing of
Medicines in Czech Republic
2007Creation of
MédiS
INTERNATIONAL
2008The start of the project
MédiS INTERNATIONAL
2009Start of the production in primary
and secondary packaging
(Tablets and Capsules )
Manufacturing and marketing of
high-value added medicines
2011Beginning of the project
2015Developpment of
DPI & Oncology products
2016Manufacturing License of
the DPI site
2017Manufacturing license of the
oncology site
2018Beginning of production and
marketing
Satisfy the local and
regional needs in
chemotherapy
and Biosimilar
medicines
100% Tunisian
Investment
> 50 M DT
Respect of Best
Manufacturing
Practices and
Security standards
Manufacturing and marketing of
high-value added medicines
Manufacturing and marketing
of medicines for West Africa
1973Creation of SIPOA
(Société Industrielle
et Pharmaceutique
de l’Ouest Africain)
1997Rhône Poulenc(Entry and majority
shareholder)
2006AfricasoinsProduction
2000Aventis Pharma
2008Winthrop Pharma
Sénégal
13 Avril
2017MédiS
Sénégal
Winthrop Pharma Senegal (Ex SANOFI) becomes MédiS SENEGAL in 2017
MédiS SENEGAL employs 170 experimented people and is specialized in manufacturing
and distribution of sterile ampoules, tablets and syrups in Senegal and sub-Saharan
Africa
Our Targets
Widen the range by the Group products-portfolio
Develop specific and essential medicines adapted to the needs of the area
Manufacturing and marketing
of medicines for West Africa
MANUFACTURING UNITS
TUNISIA
Access to the Site
Administration
MédiS I :Steril Form
MédiS II :Steril Form
MédiS III Dry forms
/ NEAPOLIS PHARMA :
Dry Powder for inhalation (DPI)
Social Bloc
Quality Control
Laboratory
Warehouse
NEAPOLIS PHARMA :
Oncology Unit
Injectable
Biotechnology
DPI
Oncology
Solid and liquid forms
MédiSI
MédiSII
MédiSIII
NEAPOLIS
First unit
5 000 m²
7 lines of production for the injectable
Forms
5 000 m²
2 lines of production of high capacity for
injectable Forms
7 000 m²
5 lines: oral solid and mono-dose liquids
automatic lines
Unité d’Oncologie : 3 700 m²
Injectable, oral and a dedicated Quality
Control Laboratory
DPI unit
Quality Control Laboratory
Warehouse
2 000 m²
chemistry , microbiology et
biotechnology
6 000 Pallets
Injectable
Biotechnology
DPI
Oncology
Solid and liquid forms
Biotechnology
Technical team : 23 specialized staff
Partnership and technology transfer with
leaders in the sector
Specially dedicated lines : Injectable Forms,
Lyophilisates, pre-filled Syringes
Dedicated quality control laboratory :
HPLC, Electrophoresis , ELISA,
UV-Spectrophotometry …
MédiS expansion intointernational markets
More than 1500 employees worldwide
More than 125 Millions dollars of Turnover / year, in more than 25 countries
Opening towards new horizons…
Commercial
presence :
SAUDI ARABIA
UAE
OMAN
JORDAN
LEBANON
YEMEN
IRAQ
SYRIA
ALGERIA
LIBYA
MOROCCO
MAURITANIA
FRANCOPHONE AFRICA
…..
TUNISIA
ALGERIA
CZECH. REP
SENEGAL
ProductionSites :
----
EXCHANGES OF EXPERTISE AND KNOW-HOW
MédiS GROUP
PORTFOLIO
INNOVATION IN THE STRATEGIC CHOICES
LYOPHILISATES
PREFILLED SYRINGES
DENTAL CARTRIDGES
ONCOLOGY
BIOTECHNOLOGYDPI
NUMBER OF MAA OF THE
GROUP WORLDWIDE : 1 235
In Tunisia
In Africa
In Midlle East
In Russia 4
280
889
62
THERAPEUTIC AREAS
CERTIFICATIONS AND
MANUFACTURING LICENSE
CERTIFICATIONS AND
MANUFACTURING LICENSE
GMP STANDARDSEuropean
SPECIFIC STANDARDSSaudi Arabia
CERTIFICATIONS AND
MANUFACTURING LICENSE
SPECIFIC STANDARDSGHC
CERTIFICATIONS AND
MANUFACTURING LICENSE
SPECIFIC STANDARDSJordan
CERTIFICATIONS AND
MANUFACTURING LICENSE
SPECIFIC STANDARDSYemen
CERTIFICATIONS AND
MANUFACTURING LICENSE
SPECIFIC STANDARDSSudan
CERTIFICATIONS AND
MANUFACTURING LICENSE
SPECIFIC STANDARDSSenegal GMP
CERTIFICATIONS AND
MANUFACTURING LICENSE
SPECIFIC STANDARDSIvory Coast
CERTIFICATIONS AND
MANUFACTURING LICENSE
RED CROSS
CERTIFICATIONS AND
MANUFACTURING LICENSE
NEAPOLIS
CERTIFICATIONS AND
MANUFACTURING LICENSE
INPHA-MEDIS
CERTIFICATIONS AND
MANUFACTURING LICENSE
Thanks